OncoAlert

Dear Colleagues,
Welcome to this Hematology Round Up from 

hashtag

#ASCO24 . WE have focused on Hematologic malignancies with 3 presentations which were presented on June 2nd, 2024

The first presentation was the Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. Facon
This trial presentation came with a concomitant publication on the New England Journal of Medicine (NEJM).
https://lnkd.in/d2dRh6Hp


The Second Presentation was the Phase 3 randomized BENEFIT study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Presented by Dr. Leleu
This trial presentation came with a concomitant publication on Nature Medicine
https://lnkd.in/dSjVvk7X


The final presentation was Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented by Dr Rodriguez-Otero



Dr. Landgren discussed how quadruple therapies showed higher rates of minimal residual disease (MRD) and longer progression-free survival compared to triplets, regardless of age and transplant eligibility, potentially making them a new standard of care for newly diagnosed Multiple Myeloma.

He emphasized the importance of minimal residual disease as an endpoint in newly diagnosed multiple myeloma, suggesting that having it as an early endpoint for accelerated approval could give patients faster access to new therapies. However, he also highlighted that bortezomib increases the rate of peripheral neuropathy.

Dr. Landgren pointed out that CD38 monoclonal antibodies narrow the gap between transplant-eligible, younger, and fit patients, and transplant-ineligible, older, and less fit patients with multiple myeloma.

Thank you for your attention and enjoy ASCO

Disclosure: This Hematology Round Up was supported by Sanofi

✅ TheLancet Commission on #ProstateCancer 
✅DESTINY-PanTumor01
✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁
✅ASCENT in Triple Negative #BreastCancer 🧪
✅Bilateral Oophorectomy  in BRCA1&2🧬
✅Racialized inequities in live birth after cancer🤰🏾
✅MITO END in Endometrial Cancer
✅Tx Patterns Advanced Urothelial Carcinoma🇺🇸
and more‼️

The OncoAlert Weekly Round Up 🚨Covering April 26- May 1st, 2024
REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration

COVERING
DESTINY-Breast06
Monarch E
US Preventive S Task force #BreastCancer Screen
@US_FDA approval of Tisotumab vedotin
NEO predict-Lung
Pushing Boundaries in ctDNA
StereotactiveRT in oligomet #KidneyCancer
Thromboembolic Risk in #ProstateCancer Patients Treated with PARP Inhibitors
@CancerCareMASCC -  @ASCO Standards and practices in metastatic #Cancer

Special Podcast:
@gu_onc &  @Uromigos at #APCCC24 

What happens when Five Friends initially brought together by oncology meet up in Lugano for #APCCC24..........Magic...thats what!

Join Renu, Declan, Brian, Tom and Gil on this insanely casual and fun conversation on the side 

The OncoAlert  Weekly Round Up
Covering April 19-25, 2024

REGISTER AT http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration

Discussing
ADCs in #LungCancer & #BreastCancer 
Out on 

@Annals_Oncology

https://annalsofoncology.org/article/S0923-7534(24)00108-X/abstract

TILS in #TNBC
https://jamanetwork.com/journals/jama/article-abstract/2816923

TROPION in #BreastCancer
https://ascopubs.org/doi/full/10.1200/JCO.23.01909

DE-REAL in #BreastCancer
https://academic.oup.com/oncolo/article/29/4/303/7444338?login=false

CheckMate9ER in #kidneycancer
https://esmoopen.com/article/S2059-7029(24)00762-2/fulltext#%20

INNOVATED out on 

@ESMO_Open

 

POP RT in #ProstateCancer
https://redjournal.org/article/S0360-3016(24)00439-5/abstract#%20

Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35333

✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM 

https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0

✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial 

https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext

✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X

✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab

https://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext

✅The Lancet Breast Cancer Commission

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext

✅Top advances of the year: Uterine cancer

https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321

The  @OncoAlert RoundUp is Out
Covering April 5th-12th, 2024

REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration

Discussing:
 

@US_FDA

  approval trastuzumab dx
Durvalumab in Small Cell #LungCancer
ALINA  #NSCLC out on 

@NEJM

 
CD70 CART in #KidneyCancer
Adagrasib Cetux in #colorectalcancer 
and more

The Top News, publications and trials in Oncology for the week of March 28- April 4, 2024

SENOMAC out in NEJM on Breast Cancer
ACS & IARC 2022 Cancer Statistics
and more

Contact 02
Embark/
GETUG 18
FORMULA 509
BRCA Away